ELC Group Announces Appointment of Dr. Siddharth Chachad
News Aug 21, 2014
ELC Group has announced the appointment of internationally acclaimed clinical pharmacologist Dr. Siddharth Chachad as Head of Global Clinical Development and Medical Affairs.
A member of the UK Faculty of Pharmaceutical Medicine, Dr. Chachad is an expert in the design and execution of pre-clinical and clinical development programme for drug products across dosage forms and therapeutic categories. Dr. Chachad has gained considerable career experience in the delivery medical services, medico-regulatory affairs and clinical development, and has worked across global clinical development strategy and operations of generics, new drugs and biosimilars. Dr. Siddharth’s extensive expertise covers all phases of clinical studies, including pre-clinical, pharmacodynamic studies, bioequivalence, PK in patients and full-blown clinical efficacy and safety studies.
“The appointment of Dr. Siddharth Chachad comes at a pivotal time for ELC Group,” said Marco Rubenstein, CEO of ELC Group. “Having been instrumental in the development of successful product registration strategies, I have no doubt that Dr. Siddarth will prove an exceptional leader of our Global Clinical Development and Medical Affairs team.”
Dr. Chachad added: “I am excited to be joining ELC Group and bringing my experience of Clinical Development and Medical Affairs to what is already a world-class team in this area.”
A renowned speaker at numerous clinical research and pharmacovigilance conferences, Dr. Chachad has authored over 25 publications.
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018